HOME >> BIOLOGY >> NEWS
Genetic modification of linseed produces healthier omega 3 and 6 fatty acids

In research reported this month in The Plant Cell, scientists succeeded in producing genetically modified linseed plants that accumulate significant levels of very long chain poly-unsaturated fatty acids (PUFA) in seed. This is the first report of the successful engineering of very long chain PUFA into an oilseed crop, and is an excellent example of how genetic engineering of agronomically important species can provide real benefits to human health and nutrition and the environment.

In research reported this month in The Plant Cell, Ernst Heinz at the University of Hamburg (Germany) and colleagues succeeded in producing genetically modified linseed plants that accumulate significant levels of very long chain poly-unsaturated fatty acids (PUFA) in seed. The work is the result of an international collaboration between scientists at several research institutions in Germany (University of Hamburg, BASF Plant Science GmbH and Forschungszentrum Borstel), Rothamsted Research Station in the U.K., and Kansas State University in the U.S. This research is an excellent example of how genetic engineering of agronomically important species can provide real benefits to human health and nutrition and the environment. As demand rises for edible oils that are low in saturated fats and high in poly-unsaturated fats, in particular very long chain omega 3- and omega 6-poly-unsaturated fats, the production of these oils in plants may reduce environmentally and economically unsustainable pressures on both wild and farmed fisheries.

Fatty acids are long straight chains of carbon atoms, ranging in length from about 12 to 22 carbons (C12 to C22). They have one water-soluble end and one oil-soluble methyl end, and are studded with hydrogen atoms along the length of the carbon chain. They are essential components of the membranes of all living organisms. Fatty acid chains that are linked by single bonds between carbon atoms are said to be "saturated" by hydrogen atoms, w
'"/>

Contact: Nancy Eckardt
neckardt@aspb.org
970-495-9918
American Society of Plant Biologists
17-Sep-2004


Page: 1 2 3

Related biology news :

1. Genetic mutations linked to the practice of burning coal in homes in China
2. Genetic differences might help distinguish thyroid cancers
3. Wiley publishes Welcome to the Genome: A Users Guide to the Genetic Past, Present, and Future
4. Genetically modified bacterium as remedy for intestinal diseases
5. Genetic analysis rewrites salamanders evolutionary history
6. Genetic map of important tree genes outlined
7. Genetically-engineered marathon mouse keeps on running
8. Genetic clues found for common congenital brain disorder
9. Genetic mutation linked to more aggressive breast cancer found more often in African-Americans
10. Genetic discovery could dramatically reduce need for liver transplants in children
11. Genetic model for devastating form of paraplegia suggests new treatments

Post Your Comments:
(Date:5/24/2013)... noise in one French Quarter neighborhood of New Orleans ... ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at ... a third-year LSUHSC doctor of audiology student, recommend that ... health. Their case study is published online in the ... ., "An important part of an audiologist,s practice is ...
(Date:5/23/2013)... world,s most popular fruit, can be made both better-tasting ... varieties. , "Working with GM tomatoes that are ... a specific compound, allows us to pinpoint exactly how ... from the John Innes Centre. , The research could ... and shelf life characteristics because even higher levels of ...
(Date:5/23/2013)... suppresses lipid synthesis in the liver, UC Irvine endocrinologists ... liver diseases. , With this finding, Dr. Ellis ... in the field. Study results appear in the May ... , "The dogma in the steroid receptor field for ... the nucleus respond to steroid hormones by regulating genes ...
Breaking Biology News(10 mins):Please do try this at home 2The world's favorite fruit only better-tasting and longer-lasting 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 Vestiage, ... lifestyle company focused on science-based research and development, ... anti-aging cosmeceuticals and nutraceuticals, announced today that it ... States for the sale of Reluma Skin Illuminating ... packet and application by sending an email to ...
(Date:5/23/2013)...  BioScrip, Inc. (NASDAQ: BIOS ) today ... 2013 Global Healthcare Conference to be held June 3-6, ... Richard Smith , President and Chief ... Chief Financial Officer, will present on Monday, June 3, ... About BioScrip BioScrip, Inc. provides comprehensive infusion ...
(Date:5/23/2013)... Ind. , May 23, 2013  Rahal Letterman ... in human cord blood stem cell banking and therapeutics, ... of the No. 16 Acorn Stairlifts Indy car driven ... for the remainder of the IZOD IndyCar 2013 season. ... (RLL) will work to support awareness of umbilical cord ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
Cached News: